Eurofins-Cerep SA

What Eurofins-Cerep SA does

Eurofins-Cerep SA is a publicly listed French société anonyme (public limited company) headquartered at 2 rue du Professeur Gargouïl, 86600 Celle L'Evescault, France. The entity was founded in 1989 and completed its initial public offering on Euronext Paris (Euronext Growth market) in February 1998 at an introduction price of €6.86, subsequently adjusted for a 5-for-1 share multiplication in July 2001. It trades under ticker ALECR (ISIN FR 0013256518) and, as of October 2018, carried a market capitalization of approximately €34 million. The company is operationally embedded within Eurofins France, a subsidiary of the larger Eurofins group, and corporate governance is led by Chairman Paul Ratcliffe, CEO Damien Vielliard, and board member Rodolphe Simonot.

The available source material consists exclusively of a corporate investor relations factsheet and contains no disclosure of products, services, customers, pricing, revenue model, headcount, geographic markets served, patents, partnerships, or technology stack. The company name preserves the historical Cerep identity (historically associated with pharmacology and drug-discovery screening services) and is hosted under the eurofins.fr corporate domain with cross-links to the Eurofins group investor relations, career, and worldwide contact infrastructure. Investor contact is routed through a Eurofins group finance mailbox ([email protected]).

As of 31 December 2023, Eurofins Cerep reported 5,044 shares outstanding, an exceptionally narrow share base for a publicly listed entity. No product, revenue, or operational KPIs are disclosed in the available material. The company appears to function as a small listed vehicle within the broader Eurofins group structure rather than as a standalone operating business with independently disclosed commercial metrics.

Name

Eurofins-Cerep SA

Legal name

Eurofins Cerep SA

Website

https://cerep.fr

Company type

Public

Founded year

1989

Operating status

Operating

Headcount range

251–500 employees

Short description

Eurofins-Cerep SA is a France-domiciled, Euronext Growth-listed public limited company (ticker ALECR), founded 1989 and operating as a subsidiary within the Eurofins France / Eurofins group structure. The available source material discloses only corporate governance and listing data; no products, customers, or revenue are described.

Ownership category

akta.pro rank

Headquarters

HQ city

Celle-lévescault

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D

Core offering

Eurofins-Cerep SA is a publicly listed French company on Euronext Growth Paris operating as a subsidiary of Eurofins France within the Eurofins group. The available source material is limited to investor relations content (corporate governance, share information, stock listing details) and does not describe specific products, services, or commercial activities offered by the company.

Differentiator

Problem solved

Functional benefit

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves5 records

Direct peers

• Eurofins Genomics: Eurofins Genomics is a sister operating entity within the Eurofins group offering genomics, sequencing, and molecular biology services. It is comparable as a sibling subsidiary that competes internally for capital allocation and customer relationships within Eurofins' life sciences services portfolio.
• Eurofins Discovery Services: Eurofins Discovery Services is the operating brand within the Eurofins group that absorbed much of the historical Cerep drug discovery and in vitro pharmacology business. It is the closest functional peer in terms of offering (screening assays, profiling, drug discovery services) and customer base (pharma and biotech R&D).
• Eurofins France SAS: Eurofins France is the immediate parent entity disclosed in the source data. It is comparable because the Cerep board, governance, and corporate structure are nested inside it, and any analysis of Cerep's strategic role must be read against Eurofins France's broader portfolio decisions.

Broad incumbents

• Evotec SE: Evotec is a European drug discovery and development contract research organization offering assay development, screening, and integrated pharmacology services. It is relevant as a public-market benchmark for the type of pharma services franchise historically associated with the Cerep brand.
• Eurofins Scientific SE: Eurofins Scientific is the ultimate parent and global operator of the Eurofins group of laboratory testing and bioanalytical services companies. It is directly comparable as the controlling entity of which Eurofins-Cerep is a subsidiary, and is the natural benchmark for any standalone valuation of the Cerep vehicle.
• Charles River Laboratories International: Charles River Labs is a major global contract research organization offering preclinical, discovery, and safety assessment services. It is comparable as a market reference for the historical Cerep capability set (drug discovery, screening, in vitro pharmacology) that Eurofins-Cerep is presumed to inherit.

Regional players

• Eurofins Lancaster Laboratories: Lancaster Laboratories is a Eurofins operating site focused on bioanalytical and pharmaceutical testing services in the US market. It is a peer in the sense that it represents an alternative internal allocation point within Eurofins for the same bioanalytical/testing demand that Eurofins-Cerep could serve.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key highlights3 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eurofins-Cerep SA